Regeneron Pharmaceuticals Files 8-K

TL;DR

REGN filed an 8-K on Feb 4, 2025, covering operations and other events.

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on February 4, 2025, reporting on results of operations, other events, and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates Regeneron Pharmaceuticals, Inc. is providing updates on its financial condition and other significant events to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard SEC disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Filer
• 0000872589 (company) — Central Index Key
• February 4, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.88 — program and declared a cash dividend of $0.88 per share on the Company's common stock
• $0.001 — n the Company's common stock, par value $0.001 per share (" Common Stock "), and Class
• $3.0 billion — he Company also announced an additional $3.0 billion share repurchase program. Item 9.01 F

Filing Documents

• regn-20250204.htm (8-K) — 27KB
• exhibit991q42024.htm (EX-99.1) — 530KB
• image0a12.jpg (GRAPHIC) — 8KB
• 0001804220-25-000007.txt ( ) — 726KB
• regn-20250204.xsd (EX-101.SCH) — 2KB
• regn-20250204_lab.xml (EX-101.LAB) — 21KB
• regn-20250204_pre.xml (EX-101.PRE) — 12KB
• regn-20250204_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 4, 2025, Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company ") issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2024. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On February 4, 2025, the Company announced that Regeneron's board of directors initiated a quarterly cash dividend program and declared a cash dividend of $0.88 per share on the Company's common stock, par value $0.001 per share (" Common Stock "), and Class A stock, par value $0.001 per share (" Class A Stock " and, together with the Common Stock, " Capital Stock "). The cash dividend will be payable on March 20, 2025 to shareholders of record of the Capital Stock as of the close of business on February 20, 2025. On February 4, 2025, the Company also announced an additional $3.0 billion share repurchase program.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, dated February 4, 202 5 , Reporting Fourth Quarter and Full Year 2024 Financial and Operating Results. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 4, 2025 REGENERON PHARMACEUTICALS, INC. By: /s/ Joseph J. LaRosa Name: Joseph J. LaRosa Title: Executive Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR